Trials / Completed
CompletedNCT02981342
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
| DRUG | LY3023414 | Administered orally |
| DRUG | Gemcitabine | Administered IV |
| DRUG | Capecitabine | Administered orally |
Timeline
- Start date
- 2017-01-12
- Primary completion
- 2018-04-20
- Completion
- 2018-11-09
- First posted
- 2016-12-05
- Last updated
- 2019-11-20
- Results posted
- 2019-06-25
Locations
32 sites across 8 countries: United States, Australia, Belgium, France, Israel, Spain, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02981342. Inclusion in this directory is not an endorsement.